Next Article in Journal
Facilitators and Barriers to Take up a COVID-19 Vaccine Booster Dose among Community-Dwelling Older Adults in Hong Kong: A Population-Based Random Telephone Survey
Next Article in Special Issue
Short-Term Side Effects and SARS-CoV-2 Infection after COVID-19 Pfizer–BioNTech Vaccine in Children Aged 5–11 Years: An Italian Real-World Study
Previous Article in Journal
Manifestation of Subclinical Extrapulmonary Tuberculosis after COVID-19 Vaccination as Supraclavicular Lymphadenopathy
Previous Article in Special Issue
Anti-SARS-CoV-2S Antibody Levels in Healthcare Workers 10 Months after the Administration of Two BNT162b2 Vaccine Doses in View of Demographic Characteristic and Previous COVID-19 Infection
Brief Report

Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination

1
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe 650-0017, Japan
2
Division of Infection Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Hospital and Graduate School of Medicine, Kobe 650-0017, Japan
3
R&D, Cellspect Co., Ltd., Morioka 020-0857, Japan
4
BioResource Center, Kobe University Hospital, Kobe 650-0047, Japan
5
Division of Molecular and Cellular Signaling, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
6
Department of Transfusion Medicine and Cell Therapy, Kobe University Hospital, Kobe 650-0017, Japan
7
Division of Medical Biophysics, Kobe University Graduate School of Health Sciences, Kobe 654-0142, Japan
8
Cancer Center, Kobe University Hospital, Kobe 650-0017, Japan
9
Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editors: Soo-Hong Lee, Hansoo Park, Jagathesh Chandra Rajendran and K.S Jaganathan
Vaccines 2022, 10(6), 965; https://doi.org/10.3390/vaccines10060965
Received: 1 May 2022 / Revised: 6 June 2022 / Accepted: 14 June 2022 / Published: 17 June 2022
(This article belongs to the Special Issue The COVID Vaccine)
Anti-CD20 antibodies react with CD20 expressed not only on malignant B cells, but also on normal B cells. It has been reported that patients treated with anti-CD20 antibodies had an insufficient response to two-dose mRNA SARS-CoV-2 vaccination. To investigate the efficacy of a third dose in these patients, we investigated serum IgG antibody titers for the S1 protein after a third vaccination in 22 patients treated with the anti-CD20 antibody who failed two-dose vaccination. Results showed that overall, 50% of patients seroconverted. Although no patient who received the third dose within 1 year of the last anti-CD20 antibody administration showed an increase in S1 antibody titer, 69% of patients who received the third dose more than 1 year after the last anti-CD20 antibody administration seroconverted. Our data show that a third dose of vaccination is effective in improving the seroconversion rate in patients treated with the anti-CD20 antibody who failed standard two-dose vaccination. View Full-Text
Keywords: SARS-CoV-2 vaccination; booster shot; anti-CD20 antibody; B-cell malignancies SARS-CoV-2 vaccination; booster shot; anti-CD20 antibody; B-cell malignancies
Show Figures

Figure 1

MDPI and ACS Style

Funakoshi, Y.; Yakushijin, K.; Ohji, G.; Hojo, W.; Sakai, H.; Watanabe, M.; Kitao, A.; Miyata, Y.; Saito, Y.; Kawamoto, S.; Yamamoto, K.; Ito, M.; Koyama, T.; Imamura, Y.; Kiyota, N.; Matsuoka, H.; Mori, Y.; Minami, H. Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination. Vaccines 2022, 10, 965. https://doi.org/10.3390/vaccines10060965

AMA Style

Funakoshi Y, Yakushijin K, Ohji G, Hojo W, Sakai H, Watanabe M, Kitao A, Miyata Y, Saito Y, Kawamoto S, Yamamoto K, Ito M, Koyama T, Imamura Y, Kiyota N, Matsuoka H, Mori Y, Minami H. Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination. Vaccines. 2022; 10(6):965. https://doi.org/10.3390/vaccines10060965

Chicago/Turabian Style

Funakoshi, Yohei, Kimikazu Yakushijin, Goh Ohji, Wataru Hojo, Hironori Sakai, Marika Watanabe, Akihito Kitao, Yoshiharu Miyata, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Taiji Koyama, Yoshinori Imamura, Naomi Kiyota, Hiroshi Matsuoka, Yasuko Mori, and Hironobu Minami. 2022. "Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination" Vaccines 10, no. 6: 965. https://doi.org/10.3390/vaccines10060965

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop